Skip to main content
Erschienen in: CNS Drugs 6/2007

01.06.2007 | Therapy In Practice

Mood and Anxiety Disorders in Patients with Myasthenia Gravis

Aetiology, Diagnosis and Treatment

verfasst von: Dr Isin Baral Kulaksizoglu

Erschienen in: CNS Drugs | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Abstract

Myasthenia gravis (MG) is a chronic, autoimmune disease involving neuromuscular junctions. It is frequently associated with symptoms such as loss of muscle strength, difficulty in respiration and swallowing, diplopia and ptosis. All chronic diseases, including MG, may have psychiatric consequences in terms of coping and adaptation. Psychiatric morbidity usually appears as anxiety disorders, such as panic disorder and generalised anxiety disorder, and as depressive disorders. However, there are very few data on the prevalence and aetiology of such psychiatric symptoms in patients with MG, and those available in the literature are generally from old studies with poor methodology.
The interaction between MG and psychiatric disorders needs to be appreciated, especially in the primary care setting, since the symptoms may overlap. MG may be under-recognised initially because the psychiatric symptoms may coincide with those of the actual disease, such as fatigue, lack of energy and shortness of breath. On the other hand, co-morbid psychiatric symptoms that appear during the course of the illness may be misdiagnosed as true myasthenic symptoms; thus, leading to unnecessary drug treatment. Differentiation of the aetiology of these symptoms might alter the treatment choice and, therefore, affect the treatment success rate and patients’ well-being. Psychiatric treatments must be carefully planned because of the risk of aggravating the underling neurological disease.
Even though there appears to be an intricate relationship between MG and psychiatric symptoms, there is very limited information on this subject. As such, prospective, randomised, controlled pharmaco/psychotherapy studies are needed to better direct the management of patients and, thus, improve quality of life during the course of the illness.
Literatur
1.
Zurück zum Zitat Kanner A. Should neurologists be trained to recognize and treat co-morbid depression of neurological disorders? Yes. Epilepsy Behav 2005;6: 303–11PubMedCrossRef Kanner A. Should neurologists be trained to recognize and treat co-morbid depression of neurological disorders? Yes. Epilepsy Behav 2005;6: 303–11PubMedCrossRef
2.
Zurück zum Zitat Cummings J, Mega M, editors. Disturbances of mood and affect in neuropsychiatry and behavioral neuroscience. Oxford: Oxford University Press, 2003: 200–28 Cummings J, Mega M, editors. Disturbances of mood and affect in neuropsychiatry and behavioral neuroscience. Oxford: Oxford University Press, 2003: 200–28
3.
Zurück zum Zitat Cummings J, Mega M, editors. Disturbances of mood and affect in neuropsychiatry and behavioral neuroscience. Oxford: Oxford University Press, 2003: 67–9 Cummings J, Mega M, editors. Disturbances of mood and affect in neuropsychiatry and behavioral neuroscience. Oxford: Oxford University Press, 2003: 67–9
4.
Zurück zum Zitat Kulaksizoglu IB, Giirvit H, Polat A, et al. Unrecognized depression in community-dwelling elderly persons in Istanbul. Int Psychogeriatr 2005; 17(2): 303–12PubMedCrossRef Kulaksizoglu IB, Giirvit H, Polat A, et al. Unrecognized depression in community-dwelling elderly persons in Istanbul. Int Psychogeriatr 2005; 17(2): 303–12PubMedCrossRef
5.
Zurück zum Zitat Kanner A, Barri JJ. The impact of mood disorders in neurological diseases: should neurologists be concerned? Epilepsy Behav 2003; 4: 3–13CrossRef Kanner A, Barri JJ. The impact of mood disorders in neurological diseases: should neurologists be concerned? Epilepsy Behav 2003; 4: 3–13CrossRef
6.
Zurück zum Zitat Kupfer DJ, Frank E. Comorbidity in depression. Acta Psychiatr Scand 2003; 418: 57–60CrossRef Kupfer DJ, Frank E. Comorbidity in depression. Acta Psychiatr Scand 2003; 418: 57–60CrossRef
7.
Zurück zum Zitat Engel AG. Acquired autoimmune myasthenia gravis. In: Engel AG, Franzini-Armstrong C, editors. Myology. New York: MacGraw-Hill, 1994: 1769–97 Engel AG. Acquired autoimmune myasthenia gravis. In: Engel AG, Franzini-Armstrong C, editors. Myology. New York: MacGraw-Hill, 1994: 1769–97
8.
Zurück zum Zitat MacDonald BK, Cockerell OC, Sander JW, et al. The incidence and life-time prevalence of neurological disorders in a prospective community-based study in UK. Brain 2000; 123: 665–76PubMedCrossRef MacDonald BK, Cockerell OC, Sander JW, et al. The incidence and life-time prevalence of neurological disorders in a prospective community-based study in UK. Brain 2000; 123: 665–76PubMedCrossRef
9.
Zurück zum Zitat Grob D. Clinical manifestations of myasthenia gravis. In: Albuquerque E, Eldefrawi A, editors. Myasthenia gravis. New York: Chapman Hall, 1985: 319–45 Grob D. Clinical manifestations of myasthenia gravis. In: Albuquerque E, Eldefrawi A, editors. Myasthenia gravis. New York: Chapman Hall, 1985: 319–45
10.
Zurück zum Zitat Seybold M. Diagnosis of myasthenia gravis. In: Engel GA, editor. Myasthenia gravis and myasthenic disorders. Contemporary neurology series. Oxford: Oxford University Press, 1999: 146–60 Seybold M. Diagnosis of myasthenia gravis. In: Engel GA, editor. Myasthenia gravis and myasthenic disorders. Contemporary neurology series. Oxford: Oxford University Press, 1999: 146–60
11.
Zurück zum Zitat Emery EJ, Szymanski HV. Psychological symptoms preceding diagnosed myasthenia gravis. Psychosomatic 1981; 22(11): 993–5 Emery EJ, Szymanski HV. Psychological symptoms preceding diagnosed myasthenia gravis. Psychosomatic 1981; 22(11): 993–5
13.
Zurück zum Zitat Rohr W. Myasthenia gravis in the frontier of psychiatric diagnosis. Psychiatr Prax 1992 Sep; (19) 5: 157–63 Rohr W. Myasthenia gravis in the frontier of psychiatric diagnosis. Psychiatr Prax 1992 Sep; (19) 5: 157–63
14.
Zurück zum Zitat Perez-Nellar J, Rodriguez A. False negatives in the diagnosis of myasthenia gravis. Rev Neurol 2000; 30(8): 712–5PubMed Perez-Nellar J, Rodriguez A. False negatives in the diagnosis of myasthenia gravis. Rev Neurol 2000; 30(8): 712–5PubMed
15.
Zurück zum Zitat Nicholson GA, Wilby J, Tennant C. Myasthenia gravis: the problem of a ‘psychiatric’ misdiagnosis. Med J Aust 1986 Jun 9; 144(12): 632–8PubMed Nicholson GA, Wilby J, Tennant C. Myasthenia gravis: the problem of a ‘psychiatric’ misdiagnosis. Med J Aust 1986 Jun 9; 144(12): 632–8PubMed
16.
Zurück zum Zitat Cassem NH. Depression. In: Hackett TP, Cassem NH, editors. Massachusetts General Hospital handbook of general hospital psychiatry. Chicago (IL): Year Book Medical Publishers, 1978: 227–61 Cassem NH. Depression. In: Hackett TP, Cassem NH, editors. Massachusetts General Hospital handbook of general hospital psychiatry. Chicago (IL): Year Book Medical Publishers, 1978: 227–61
17.
Zurück zum Zitat Paul RH, Cohen RA, Goldstein JM, et al. Severity of selfevaluative and vegetative symptoms of depression in myasthenia gravis. J Neuropsychiatry Clin Neurosci 2000; 12(4): 499–501PubMedCrossRef Paul RH, Cohen RA, Goldstein JM, et al. Severity of selfevaluative and vegetative symptoms of depression in myasthenia gravis. J Neuropsychiatry Clin Neurosci 2000; 12(4): 499–501PubMedCrossRef
18.
Zurück zum Zitat Bergonzi P, Mazza S, Mennuni G, et al. Central nervous system involvement in myasthenia gravis. Ann N Y Acad Sci 1981; 377: 810–1CrossRef Bergonzi P, Mazza S, Mennuni G, et al. Central nervous system involvement in myasthenia gravis. Ann N Y Acad Sci 1981; 377: 810–1CrossRef
19.
Zurück zum Zitat Papazian O. Rapid eye movement sleep alterations in myasthenia gravis. Neurology 1976; 26: 311–6PubMedCrossRef Papazian O. Rapid eye movement sleep alterations in myasthenia gravis. Neurology 1976; 26: 311–6PubMedCrossRef
20.
Zurück zum Zitat Tucker DM, Roeltgen DP, Wann PD, et al. Memory dysfunction in myasthenia gravis: evidence for central cholinergic effects. Neurology 1988; 38: 1173–7PubMedCrossRef Tucker DM, Roeltgen DP, Wann PD, et al. Memory dysfunction in myasthenia gravis: evidence for central cholinergic effects. Neurology 1988; 38: 1173–7PubMedCrossRef
21.
Zurück zum Zitat Davidov-Lusting M, Klinghoffer V, Kaplan-Dinur A, et al. Memory abnormalities in myasthenia gravis: possible fatigue of central nervous system cholinergic circuits. Autoimmunity 1992; 14(1): 85–6PubMedCrossRef Davidov-Lusting M, Klinghoffer V, Kaplan-Dinur A, et al. Memory abnormalities in myasthenia gravis: possible fatigue of central nervous system cholinergic circuits. Autoimmunity 1992; 14(1): 85–6PubMedCrossRef
22.
Zurück zum Zitat Keesey J. Does myasthenia gravis affect the brain? J Neurological Sciences 1999; 170: 77–89CrossRef Keesey J. Does myasthenia gravis affect the brain? J Neurological Sciences 1999; 170: 77–89CrossRef
23.
Zurück zum Zitat Groves M, Muskin P. Psychological responses to illness. In: Levenson J, editor. Textbook of psychosomatic medicine. Washington, DC: American Psychiatric Publishing, 2005: 67–87 Groves M, Muskin P. Psychological responses to illness. In: Levenson J, editor. Textbook of psychosomatic medicine. Washington, DC: American Psychiatric Publishing, 2005: 67–87
24.
Zurück zum Zitat Lipowski ZJ. Physical illness: the individual and coping process. Psychiatry Med 1970; 1: 91–102PubMedCrossRef Lipowski ZJ. Physical illness: the individual and coping process. Psychiatry Med 1970; 1: 91–102PubMedCrossRef
25.
Zurück zum Zitat Meyer E. Psychological disturbances in myasthenia gravis: a predictive study. Ann N Y Acad Sci 1966; 135: 417–23PubMedCrossRef Meyer E. Psychological disturbances in myasthenia gravis: a predictive study. Ann N Y Acad Sci 1966; 135: 417–23PubMedCrossRef
26.
Zurück zum Zitat Paradis C, Friedman S, Lazar RM, et al. Anxiety disorders in a neuromuscular a clinic. Am J Psychiatry 1993; 150(7): 1102–4PubMed Paradis C, Friedman S, Lazar RM, et al. Anxiety disorders in a neuromuscular a clinic. Am J Psychiatry 1993; 150(7): 1102–4PubMed
27.
Zurück zum Zitat Sneddon J. Myasthenia gravis: a study of social, medical and emotional problems in 26 patients. Lancet 1980: 526-8 Sneddon J. Myasthenia gravis: a study of social, medical and emotional problems in 26 patients. Lancet 1980: 526-8
28.
Zurück zum Zitat MacKenzie KR, Martin MJ, Howard FM. Myasthenia gravis: psychiatric concomitants. Can Med Assoc J 1969; 100: 988–91PubMed MacKenzie KR, Martin MJ, Howard FM. Myasthenia gravis: psychiatric concomitants. Can Med Assoc J 1969; 100: 988–91PubMed
29.
Zurück zum Zitat Marcus J. The interrelations of myasthenia gravis and psychiatric stress: presentation of a case. Israel Med J 1962; 21: 178–83PubMed Marcus J. The interrelations of myasthenia gravis and psychiatric stress: presentation of a case. Israel Med J 1962; 21: 178–83PubMed
30.
Zurück zum Zitat Oosterhuis HJ, Wilde GJS. Psychiatric aspects of myasthenia gravis. Psychiatr Neurol Neurochir 1964; 67: 484–96PubMed Oosterhuis HJ, Wilde GJS. Psychiatric aspects of myasthenia gravis. Psychiatr Neurol Neurochir 1964; 67: 484–96PubMed
31.
Zurück zum Zitat Magni G, Micaglio G, Ceccato MB, et al. The role of life events in myasthenia gravis outcome: a one-year longitudinal study. Acta Neurol Scand 1989; 79: 288–91PubMedCrossRef Magni G, Micaglio G, Ceccato MB, et al. The role of life events in myasthenia gravis outcome: a one-year longitudinal study. Acta Neurol Scand 1989; 79: 288–91PubMedCrossRef
32.
Zurück zum Zitat Osserman KE, Genkins G. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med 1971; 38: 497PubMed Osserman KE, Genkins G. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med 1971; 38: 497PubMed
33.
Zurück zum Zitat Knieling J, Weiss H, Faller H, et al. Psychosocial causal attributions by myasthenia gravis patients: a longitudinal study of the significance of subjective illness theories after diagnosis and in the follow up. Psychother Psychosom Med Psychol 1995 Nov; 45(11): 373–80PubMed Knieling J, Weiss H, Faller H, et al. Psychosocial causal attributions by myasthenia gravis patients: a longitudinal study of the significance of subjective illness theories after diagnosis and in the follow up. Psychother Psychosom Med Psychol 1995 Nov; 45(11): 373–80PubMed
34.
Zurück zum Zitat Knieling J, Weiss H, Faller H, et al. Follow up of myasthenia gravis: results of a longitudinal study of significance of psychosocial predictors. Nervenarzt 1998 Feb; 69(2): 137–44PubMedCrossRef Knieling J, Weiss H, Faller H, et al. Follow up of myasthenia gravis: results of a longitudinal study of significance of psychosocial predictors. Nervenarzt 1998 Feb; 69(2): 137–44PubMedCrossRef
35.
Zurück zum Zitat Magni G, Micaglio G, Lalli R, et al. Psychiatric disturbances associated with myasthenia gravis. Acta Psychiatr Scand 1988; 77: 443–5PubMedCrossRef Magni G, Micaglio G, Lalli R, et al. Psychiatric disturbances associated with myasthenia gravis. Acta Psychiatr Scand 1988; 77: 443–5PubMedCrossRef
36.
Zurück zum Zitat American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980
37.
Zurück zum Zitat Doering S, Henze T, Schüssler G. Coping with illness in myasthenia gravis. Nervenarzt 1993 Oct; 64(10): 640–7PubMed Doering S, Henze T, Schüssler G. Coping with illness in myasthenia gravis. Nervenarzt 1993 Oct; 64(10): 640–7PubMed
38.
Zurück zum Zitat American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed., rev. Washington, DC: American Psychiatric Association, 1987 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed., rev. Washington, DC: American Psychiatric Association, 1987
40.
Zurück zum Zitat Eren I, Kulaksizoglu IB, Anuk D, et al. Post traumatic stress disorder in myasthenia gravis patients [abstract]. ESTSS 6th European Congress on Traumatic Stress; 1999 Jun 5–8: Istanbul, 147-8 Eren I, Kulaksizoglu IB, Anuk D, et al. Post traumatic stress disorder in myasthenia gravis patients [abstract]. ESTSS 6th European Congress on Traumatic Stress; 1999 Jun 5–8: Istanbul, 147-8
41.
Zurück zum Zitat Diagnostic and statistical manual of mental disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association, 2000 Diagnostic and statistical manual of mental disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association, 2000
42.
Zurück zum Zitat Spitzer RL, Williams JB, Gibbon M, et al. The structured clinical interview for DSMIII-R (SCID-I): history, rationale, and description. Arch Gen Psychiatry 1992; 49: 624PubMedCrossRef Spitzer RL, Williams JB, Gibbon M, et al. The structured clinical interview for DSMIII-R (SCID-I): history, rationale, and description. Arch Gen Psychiatry 1992; 49: 624PubMedCrossRef
43.
Zurück zum Zitat Rohr W. Situational anxiety in myasthenia gravis. Psychother Psycosom Med Psychol 1993 Apr; 43 (3–4): 93–9 Rohr W. Situational anxiety in myasthenia gravis. Psychother Psycosom Med Psychol 1993 Apr; 43 (3–4): 93–9
44.
Zurück zum Zitat Paul R, Cohen R, Goldstein J, et al. Severity of mood, self evaluative and vegetative symptoms of depression in myasthenia gravis. J Neuropsychiatry Clin Neurosci 2000 Fall; 12(4): 499–501PubMedCrossRef Paul R, Cohen R, Goldstein J, et al. Severity of mood, self evaluative and vegetative symptoms of depression in myasthenia gravis. J Neuropsychiatry Clin Neurosci 2000 Fall; 12(4): 499–501PubMedCrossRef
45.
Zurück zum Zitat Paul R, Nash J, Cohen R. Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve 2001 Apr; 24(4): 512–6PubMedCrossRef Paul R, Nash J, Cohen R. Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve 2001 Apr; 24(4): 512–6PubMedCrossRef
46.
Zurück zum Zitat Skeie O, Apolstolski S, Evoli A, et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2006; 13(7): 691–9PubMedCrossRef Skeie O, Apolstolski S, Evoli A, et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2006; 13(7): 691–9PubMedCrossRef
47.
Zurück zum Zitat Brown ES, Suppes T. Mood symptoms during corticosteroid therapy: a review. Harvard Rev Psych 1998; 5: 239–46CrossRef Brown ES, Suppes T. Mood symptoms during corticosteroid therapy: a review. Harvard Rev Psych 1998; 5: 239–46CrossRef
48.
Zurück zum Zitat Schmidt LA, Fox NA, Goldberg MC, et al. Effects of acute prednisone administration on memory, attention, and emotion in healthy human adults. Psychoneuroimmunol 1999; 24(4): 461–83 Schmidt LA, Fox NA, Goldberg MC, et al. Effects of acute prednisone administration on memory, attention, and emotion in healthy human adults. Psychoneuroimmunol 1999; 24(4): 461–83
49.
Zurück zum Zitat Warrington TP, Botswick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc 2006; 81(10): 1361–7PubMedCrossRef Warrington TP, Botswick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc 2006; 81(10): 1361–7PubMedCrossRef
50.
Zurück zum Zitat Schwartz ML, Cahill R. Psychopathology associated with myasthenia gravis and its treatment by psychotherapeutically oriented group counseling. J Chron Dis 1971; 24: 543–52PubMedCrossRef Schwartz ML, Cahill R. Psychopathology associated with myasthenia gravis and its treatment by psychotherapeutically oriented group counseling. J Chron Dis 1971; 24: 543–52PubMedCrossRef
51.
Zurück zum Zitat Kütemeyer M. Symptom changes during the psychotherapy of patients with myasthenia gravis. Psychother Psychosom 1979; 32: 279–86PubMedCrossRef Kütemeyer M. Symptom changes during the psychotherapy of patients with myasthenia gravis. Psychother Psychosom 1979; 32: 279–86PubMedCrossRef
52.
Zurück zum Zitat Achiron A, Barak Y, Noy S, et al. Fluoxetine treatment for weight reduction in steroid-induced obesity: a pilot study in myasthenia gravis patients. Euro Psychopharmacol 1999; 9: 111–3 Achiron A, Barak Y, Noy S, et al. Fluoxetine treatment for weight reduction in steroid-induced obesity: a pilot study in myasthenia gravis patients. Euro Psychopharmacol 1999; 9: 111–3
53.
Zurück zum Zitat Kulaksizoglu IB, Aldemir D, Parman Y, et al. Citalopram treatment of depression in myasthenia gravis patients: an open study [abstract]. European Congress of Neuropsychopharmacology; 2005 Oct 22–26; Amsterdam, 426 Kulaksizoglu IB, Aldemir D, Parman Y, et al. Citalopram treatment of depression in myasthenia gravis patients: an open study [abstract]. European Congress of Neuropsychopharmacology; 2005 Oct 22–26; Amsterdam, 426
54.
Zurück zum Zitat Seybold M. Treatment of myasthenia gravis. In: Engel GA, editor. Myasthenia gravis and myasthenic disorders. Contemporary neurology series. Oxford: Oxford University Press, 1999: 167–201 Seybold M. Treatment of myasthenia gravis. In: Engel GA, editor. Myasthenia gravis and myasthenic disorders. Contemporary neurology series. Oxford: Oxford University Press, 1999: 167–201
55.
Zurück zum Zitat Argov Z, Mastaglia FL. Disorders of neuromuscular transmission caused by drugs. N Engl J Med 1979; 30: 409–13 Argov Z, Mastaglia FL. Disorders of neuromuscular transmission caused by drugs. N Engl J Med 1979; 30: 409–13
56.
Zurück zum Zitat Howard JR. Adverse drug effects on neuromuscular transmission. Sem Neurol 1990; 10: 89–102CrossRef Howard JR. Adverse drug effects on neuromuscular transmission. Sem Neurol 1990; 10: 89–102CrossRef
57.
Zurück zum Zitat McQuillen MP, Gross M, Johns RJ. Chlorpromazine-induced weakness in myasthenia gravis. Arch Neurol 1963; 8: 286–90PubMedCrossRef McQuillen MP, Gross M, Johns RJ. Chlorpromazine-induced weakness in myasthenia gravis. Arch Neurol 1963; 8: 286–90PubMedCrossRef
58.
Zurück zum Zitat Argov Z, Yaari Y. The action of chlorpromazine at an isolated cholinergic synapse. Brain Research 1979; 164: 227–36PubMedCrossRef Argov Z, Yaari Y. The action of chlorpromazine at an isolated cholinergic synapse. Brain Research 1979; 164: 227–36PubMedCrossRef
59.
Zurück zum Zitat Kramer M. Hypnotic medication in the treatment of chronic insomnia: non nocere! Doesn’t anyone care? Sleep Med Rev 2000 Dec; 4(6): 529–41PubMedCrossRef Kramer M. Hypnotic medication in the treatment of chronic insomnia: non nocere! Doesn’t anyone care? Sleep Med Rev 2000 Dec; 4(6): 529–41PubMedCrossRef
60.
Zurück zum Zitat Neil JF, Himmelhoch JM, Licata SM. Emergence of myasthenia gravis during treatment with lithium carbonate. Arch Gen Psychiatry 1976; 33: 1090–2PubMedCrossRef Neil JF, Himmelhoch JM, Licata SM. Emergence of myasthenia gravis during treatment with lithium carbonate. Arch Gen Psychiatry 1976; 33: 1090–2PubMedCrossRef
61.
Zurück zum Zitat Granacher RP. Neuromuscular problems associated with lithium. Am J Psychiatry 1977; 134: 702PubMed Granacher RP. Neuromuscular problems associated with lithium. Am J Psychiatry 1977; 134: 702PubMed
62.
Zurück zum Zitat Lipton ID. Myasthenia gravis unmasked by lithium carbonate [letter]. J Clin Psychopharmacol 1987; 7: 57PubMedCrossRef Lipton ID. Myasthenia gravis unmasked by lithium carbonate [letter]. J Clin Psychopharmacol 1987; 7: 57PubMedCrossRef
63.
Zurück zum Zitat Vizi ES, Illes P, Ronai A, et al. The effect of lithium on acetylcholine release and synthesis. Neuropharmacology 1972; 11: 521–30PubMedCrossRef Vizi ES, Illes P, Ronai A, et al. The effect of lithium on acetylcholine release and synthesis. Neuropharmacology 1972; 11: 521–30PubMedCrossRef
64.
Zurück zum Zitat Hill GE, Wong KC, Hodges MR. Potentiation of succinylcholine neuromuscular blockage by lithium carbonate. Anesthesiology 1976; 44: 439–42PubMedCrossRef Hill GE, Wong KC, Hodges MR. Potentiation of succinylcholine neuromuscular blockage by lithium carbonate. Anesthesiology 1976; 44: 439–42PubMedCrossRef
65.
Zurück zum Zitat Lai CW, Leppik IE, Jenkins DC, et al. Epilepsy, myasthenia gravis, and effect of plasmapheresis on antiepileptic drug concentrations. Arch Neurol 1990 Jan; 47(1): 66–8PubMedCrossRef Lai CW, Leppik IE, Jenkins DC, et al. Epilepsy, myasthenia gravis, and effect of plasmapheresis on antiepileptic drug concentrations. Arch Neurol 1990 Jan; 47(1): 66–8PubMedCrossRef
66.
Zurück zum Zitat Siddiqi ZA, Holt A, Ahmed SN. Effect of plasma exchange on carbamazepine levels in a patient with myasthenia gravis and epilepsy. Epilepsia 2005 Nov; 46(11): 1841–2PubMedCrossRef Siddiqi ZA, Holt A, Ahmed SN. Effect of plasma exchange on carbamazepine levels in a patient with myasthenia gravis and epilepsy. Epilepsia 2005 Nov; 46(11): 1841–2PubMedCrossRef
67.
Zurück zum Zitat Pande AC, Grunhaus LJ. ECT for depression in the presence of myasthenia gravis. Convuls Ther 1990; 6(2): 172–5PubMed Pande AC, Grunhaus LJ. ECT for depression in the presence of myasthenia gravis. Convuls Ther 1990; 6(2): 172–5PubMed
68.
Zurück zum Zitat Calarge CA, Crowe RR. Electroconvulsive therapy in myasthenia gravis. Ann Clin Psychiatry 2004 Oct–Dec; 16(4): 225–7PubMedCrossRef Calarge CA, Crowe RR. Electroconvulsive therapy in myasthenia gravis. Ann Clin Psychiatry 2004 Oct–Dec; 16(4): 225–7PubMedCrossRef
Metadaten
Titel
Mood and Anxiety Disorders in Patients with Myasthenia Gravis
Aetiology, Diagnosis and Treatment
verfasst von
Dr Isin Baral Kulaksizoglu
Publikationsdatum
01.06.2007
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 6/2007
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200721060-00004

Weitere Artikel der Ausgabe 6/2007

CNS Drugs 6/2007 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.